The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for ...

Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its ...

Fintel reports that on September 26, 2024, Rodman & Renshaw upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...

Barclays analyst Peter Lawson has reiterated their neutral stance on BMEA stock, giving a Hold rating yesterday. Peter Lawson has given his ...

Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing ...

REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent ...

Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug.

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

NDAQ:BMEA) Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $8.26 which represents a slight increase of $0.28 or 3.51% from the prior close of $7.98. The stock opened at $8.03 and touched a ...